Summary

This article discusses the results of an analysis of data from a subgroup of patients in the TRITON-TIMI 38 study [NCT00097591; Wiviott et al. N Engl J Med 2007] who were receiving proton pump inhibitor therapy in addition to a thienopyridine (prasugrel or clopidogrel). The results showed no association between PPI use and an increased risk of cardiovascular events [O'Donoghue M et al. Lancet 2009].